3 results
Approved WMOCompleted
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Approved WMORecruiting
To evaluate the safety and efficacy of intravenously administered FFP104 in subjects with active Crohn*s disease following repeat doses of FFP104.
Approved WMOCompleted
To evaluate the safety and tolerability of FFP104 in PBC subjects following repeat doses of FFP104